Evidence map›Paper›PMID 29803996›Full record

ArticleEuropean journal of medicinal chemistry2018

SAR studies on truxillic acid mono esters as a new class of antinociceptive agents targeting fatty acid binding proteins.

Su Yan, Matthew W Elmes, Simon Tong, Kongzhen Hu, Monaf Awwa, Gary Y H Teng, Yunrong Jing, Matthew Freitag, Qianwen Gan, Timothy Clement and 17 more

Open access · greenAbstract read
In one paragraph

Article in European journal of medicinal chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 46 citations in OpenAlex.

  1. Trial
  2. Review
  3. Evaluating FABP5 as a Therapeutic Target for Pain Management.European journal of pain (London, England) · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 3 institutions in 1 country.

Su YanDepartment of Chemistry, Stony Brook University, Stony Brook, NY, 11794-3400, United states.
Matthew W ElmesDepartments of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY, 11794-5215, United states.
Simon TongDepartment of Chemistry, Stony Brook University, Stony Brook, NY, 11794-3400, United states.
Kongzhen HuInstitute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, NY, 11794-3400, United states.
Monaf AwwaDepartment of Chemistry, Stony Brook University, Stony Brook, NY, 11794-3400, United states.
Gary Y H TengInstitute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, NY, 11794-3400, United states.
Yunrong JingInstitute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, NY, 11794-3400, United states.
Matthew FreitagDepartment of Chemistry, Stony Brook University, Stony Brook, NY, 11794-3400, United states.
Qianwen GanDepartment of Chemistry, Stony Brook University, Stony Brook, NY, 11794-3400, United states.
Timothy ClementDepartment of Chemistry, Stony Brook University, Stony Brook, NY, 11794-3400, United states.
Longfei WeiDepartment of Chemistry, Stony Brook University, Stony Brook, NY, 11794-3400, United states.
Joseph M SweeneyDepartments of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY, 11794-5215, United states.
Olivia M JosephDepartments of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY, 11794-5215, United states.
Joyce CheDepartments of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY, 11794-5215, United states.
Gregory S CarbonettiDepartments of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY, 11794-5215, United states.
Liqun WangDepartments of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY, 11794-5215, United states.
Diane M BogdanDepartment of Anesthesiology, Stony Brook University, Stony Brook, NY, 11794-8480, United states.
Jerome FalconeDepartment of Anesthesiology, Stony Brook University, Stony Brook, NY, 11794-8480, United states.
Norbert SmietaloDepartment of Anesthesiology, Stony Brook University, Stony Brook, NY, 11794-8480, United states.
Yuchen ZhouApplied Mathematics and Statistics, Stony Brook University, Stony Brook, NY, 11794-3600, United states.
Brian RalphApplied Mathematics and Statistics, Stony Brook University, Stony Brook, NY, 11794-3600, United states.
Hao-Chi HsuCryo-EM Structural Biology Laboratory, Van Andel Research Institute, Grand Rapids, MI, 49503, United states.
Huilin LiCryo-EM Structural Biology Laboratory, Van Andel Research Institute, Grand Rapids, MI, 49503, United states.
Robert C RizzoApplied Mathematics and Statistics, Stony Brook University, Stony Brook, NY, 11794-3600, United states; Institute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, NY, 11794-3400, United states.
Dale G DeutschDepartments of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY, 11794-5215, United states; Institute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, NY, 11794-3400, United states.
Martin KaczochaDepartments of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY, 11794-5215, United states; Department of Anesthesiology, Stony Brook University, Stony Brook, NY, 11794-8480, United states; Institute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, NY, 11794-3400, United states.
Iwao OjimaDepartment of Chemistry, Stony Brook University, Stony Brook, NY, 11794-3400, United states; Institute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, NY, 11794-3400, United states. Electronic address: iwao.ojima@stonybrook.edu.
Stony Brook University · USApplied Mathematics (United States) · USVan Andel Institute · US

Funding

Anandamide Transport InhibitorsR01DA035923 · NIDA · STATE UNIVERSITY NEW YORK STONY BROOK · PI KACZOCHA, MARTIN · 2013 to 2017
$3.8M
FABPs: Novel Roles in Pain and InflammationR01DA035949 · NIDA · STATE UNIVERSITY NEW YORK STONY BROOK · PI KACZOCHA, MARTIN · 2014 to 2022
$3.0M
MOLECULAR AND CELLULAR BIOLOGY TRAINING PROGRAMT32GM008468 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI NEIMAN, AARON M · 1997 to 2016
$1.9M
NIDA NIH HHS R01 DA035923NIDA NIH HHS R01 DA035949NIGMS NIH HHS T32 GM008468
6 · The paper itself

Abstract

Fatty acid binding proteins (FABPs) serve as critical modulators of endocannabinoid signaling by facilitating the intracellular transport of anandamide and whose inhibition potentiates anandamide signaling. Our previous work has identified a novel small-molecule FABP inhibitor, α-truxillic acid 1-naphthyl monoester (SB-FI-26, 3) that has shown efficacy as an antinociceptive and anti-inflammatory agent in rodent models. In the present work, we have performed an extensive SAR study on a series of 3-analogs as novel FABP inhibitors based on computer-aided inhibitor drug design and docking analysis, chemical synthesis and biological evaluations. The prediction of binding affinity of these analogs to target FABP3, 5 and 7 isoforms was performed using the AutoDock 4.2 program, using the recently determined co-crystal structures of 3 with FABP5 and FABP7. The compounds with high docking scores were synthesized and evaluated for their activities using a fluorescence displacement assay against FABP3, 5 and 7. During lead optimization, compound 3l emerged as a promising compound with the Ki value of 0.21 μM for FABP 5, 4-fold more potent than 3 (Ki, 0.81 μM). Nine compounds exhibit similar or better binding affinity than 3, including compounds 4b (Ki, 0.55 μM) and 4e (Ki, 0.68 μM). Twelve compounds are selective for FABP5 and 7 with >10 μM Ki values for FABP3, indicating a safe profile to avoid potential cardiotoxicity concerns. Compounds 4f, 4j and 4k showed excellent selectivity for FABP5 and would serve as other new lead compounds. Compound 3a possessed high affinity and high selectivity for FABP7. Compounds with moderate to high affinity for FABP5 displayed antinociceptive effects in mice while compounds with low FABP5 affinity lacked in vivo efficacy. In vivo pain model studies in mice revealed that exceeding hydrophobicity significantly affects the efficacy. Thus, among the compounds with high affinity to FABP5 in vitro, the compounds with moderate hydrophobicity were identified as promising new lead compounds for the next round of optimization, including compounds 4b and 4j. For select cases, computational analysis of the observed SAR, especially the selectivity of new inhibitors to particular FABP isoforms, by comparing docking poses, interaction map, and docking energy scores has provided useful insights.

Indexed as

AnalgesicsAnimalsComputer-Aided DesignCyclobutanesDose-Response Relationship, DrugDrug DesignEstersFatty Acid-Binding ProteinsHumansMaleMiceMice, Inbred C57BLMice, KnockoutMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAnalgesicsCyclobutanesEstersFatty Acid-Binding Proteinstruxillic acidAnti-inflammatory agentAnti-nociceptive agentComputer-aided designFABP inhibitorFatty acid binding proteinMolecular dockingSAR study

Identifiers

PMID29803996
PMCPMC5999033
OpenAlexW2803283014

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.